Thermo Fisher (TMO) announced an expansion of their strategic partnership with Sanofi (SNY) to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will expand use of the site to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity. The Ridgefield site is a sterile fill-finish and packaging facility with a team of more than 200 employees who will join Thermo Fisher following the completion of the transaction. The transaction is expected to be completed in the second half of 2025, subject to customary closing conditions. Upon completion of the transaction, Sanofi’s Ridgefield facility will become part of Thermo Fisher’s pharma services business within its Laboratory Products and Biopharma Services segment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- CoreWeave, Vertiv, Thermo Fisher, Altria, Bloom: Trending by Analysts
- CoreWeave initiated, Texas Instruments upgraded: Wall Street’s top analyst calls
- Scotiabank upgrades Thermo Fisher with ‘worst-case’ priced in
- Thermo Fisher upgraded to Outperform from Sector Perform at Scotiabank
- 3 Best Undervalued Stocks to Buy Now, 7/9/2025, According to Analysts